P38MAPK inhibition: A new combined approach to reduce neuroblastoma resistance under etoposide treatment

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Marengo, B ^a   De Ciucis, C G ^a   Ricciarelli, R ^a   Furfaro, A L ^a   Colla, R ^a   Canepa, E ^a   Traverso, N ^a   Marinari, U M ^a   Pronzato, M A ^a   Domenicotti, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Etoposide; MAPK; Neuroblastoma

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CHEMOKINE RECEPTOR; CYCLOOXYGENASE 2; ETOPOSIDE; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR PROTEIN;

ARTICLE; CARCINOGENICITY; CELL MIGRATION; CELL VIABILITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; APOPTOSIS; CANCER STAGING; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; ECONOMICS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVOUS SYSTEM TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; NEOPLASM STAGING; NERVOUS SYSTEM NEOPLASMS; NEUROBLASTOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84876887873     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.118     Document Type: Article

References (58)

1. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011; 8: 127
2. Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008; 131: 3092-3102
3. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM et al. Interleukin-17 production in central nervous system-Infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146-155
4. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008; 105: 9041-9046
5. Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J Neurosci Res 2005; 81: 363-373
6. Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: New concepts for signaling. Trends Biochem Sci 2010; 35: 601-608
7. Webb M, Luo L, Ma JY, Tham CS. Genetic deletion of fatty acid amide hydrolase results in improved long-Term outcome in chronic autoimmune encephalitis. Neurosci Lett 2008; 439: 106-110
8. Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol 2009; 182: 7625-7633
9. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. Functional and pathological roles of the 12-And 15-lipoxygenases. Prog Lipid Res 2011; 50: 115-131
10. Brash AR. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999; 274: 23679-23682
11. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91: 439-446
12. Pantaleo P, Marra F, Vizzutti F, Spadoni S, Ciabattoni G, Galli C et al. Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. Clin Sci (Lond) 2004; 106: 27-34
13. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378-382
14. Nishiyama M, Watanabe T, Ueda N, Tsukamoto H, Watanabe K. Arachidonate 12-lipoxygenase is localized in neurons, glial cells, and endothelial cells of the canine brain. J Histochem Cytochem 1993; 41: 111-117
15. Bendani MK, Palluy O, Cook-Moreau J, Beneytout JL, Rigaud M, Vallat JM. Localization of 12-lipoxygenase mRNA in cultured oligodendrocytes and astrocytes by in situ reverse transcriptase and polymerase chain reaction. Neurosci Lett 1995; 189: 159-162
16. Chu J, Zhuo JM, Pratico D. Transcriptional regulation of beta-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol 2012; 71: 57-67
17. Yang H, Zhuo JM, Chu J, Chinnici C, Pratico D. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry 2010; 68: 922-929
18. Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997; 19: 453-463
19. Emerson MR, LeVine SM. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 2004; 1021: 140-145
20. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424
21. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012; 23: 351-363
22. Esposito E, Rinaldi B, Mazzon E, Donniacuo M, Impellizzeri D, Paterniti I et al. Antiinflammatory effect of simvastatin in an experimental model of spinal cord trauma: Involvement of PPAR-Alpha. J Neuroinflammation 2012; 9: 81
23. Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation 2012; 9: 63
24. Deschamps JD, Kenyon VA, Holman TR. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem 2006; 14: 4295-4301
25. van Leyen K, Kim HY, Lee SR, Jin G, Arai K, Baicalein LoEH. and 12/15-lipoxygenase in the ischemic brain. Stroke 2006; 37: 3014-3018
26. Miller SD, Karpus WJ. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol Today 1994; 15: 356-361
27. van Horssen J, Singh S, van der Pol S, Kipp M, Lim JL, Peferoen L et al. Clusters of activated microglia in normal-Appearing white matter show signs of innate immune activation. J Neuroinflammation 2012; 9: 156
28. Tian L, Ma L, Kaarela T, Li Z. Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J Neuroinflammation 2012; 9: 155
29. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hovelmeyer N et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005; 11: 146-152
30. Xiao Y, Xu J, Wang S, Mao C, Jin M, Ning G et al. Genetic ablation of steroid receptor coactivator-3 promotes PPAR-beta-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis. Glia 2010; 58: 932-942
31. Yang Y, Lovett-Racke AE, Racke MK. Regulation of immune responses and autoimmune encephalomyelitis by PPARs. PPAR Res 2010; 2010: 104705
32. Xu YW, Sun L, Liang H, Sun GM, Cheng Y. 12/15-Lipoxygenase inhibitor baicalein suppresses PPAR gamma expression and nuclear translocation induced by cerebral ischemia/reperfusion. Brain Res 2010; 1307: 149-157
33. Poulsen L, Siersbaek M, Mandrup S. PPARs: Fatty acid sensors controlling metabolism. Semin Cell Dev Biol 2012; 23: 631-639
34. Defaux A, Zurich MG, Braissant O, Honegger P, Monnet-Tschudi F. Effects of the PPARbeta agonist GW501516 in an in vitro model of brain inflammation and antibody-Induced demyelination. J Neuroinflammation 2009; 6: 15
35. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-Activated receptors (PPARs): Tissue distribution of PPAR-Alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366
36. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000; 164: 1364-1371
37. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM et al. Peroxisome proliferator-Activated receptor-gamma activators inhibit IFN-gamma-Induced expression of the T cell-Active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164: 6503-6508
38. Natarajan C, Bright JJ. Peroxisome proliferator-Activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002; 3: 59-70
39. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-Inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 2004; 75: 478-485
40. Harris SG, Phipps RP. Peroxisome proliferator-Activated receptor gamma (PPAR-gamma) activation in naive mouse T cells induces cell death. Ann N Y Acad Sci 2000; 905: 297-300
41. Tautenhahn A, Brune B, von Knethen A. Activation-Induced PPARgamma expression sensitizes primary human T cells toward apoptosis. J Leukoc Biol 2003; 73: 665-672
42. Kuhn H, Thiele BJ. The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. FEBS Lett 1999; 449: 7-11
43. Sun D, Funk CD. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J Biol Chem 1996; 271: 24055-24062
44. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 110: 2024-2031
45. Bolick DT, Orr AW, Whetzel A, Srinivasan S, Hatley ME, Schwartz MA et al. 12/15-Lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol 2005; 25: 2301-2307
46. Poeckel D, Zemski Berry KA, Murphy RC, Funk CD. Dual 12/15-And 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice. J Biol Chem 2009; 284: 21077-21089
47. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 1995; 44: 1447-1457
48. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest 1999; 103: 1431-1436
49. Rong S, Cao Q, Liu M, Seo J, Jia L, Boudyguina E et al. Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis. J Lipid Res 2012; 53: 686-695
50. Andersson CK, Claesson HE, Rydell-Tormanen K, Swedmark S, Hallgren A, Erjefalt JS. Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and remodeling. Am J Respir Cell Mol Biol 2008; 39: 648-656
51. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 2008; 22: 1169-1178
52. Mirshafiey A, Jadidi-Niaragh F. Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis. Immunopharmacol Immunotoxicol 2010; 32: 219-227
53. Polak PE, Kalinin S, Dello Russo C, Gavrilyuk V, Sharp A, Peters JM et al. Protective effects of a peroxisome proliferator-Activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunology 2005; 168: 65-75
54. Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, Johnson A et al. Peroxisome proliferatoractivated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 2010; 207: 1599-1608
55. Tsai TH, Liu SC, Tsai PL, Ho LK, Shum AY, Chen CF. The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: A microdialysis study. Br J Pharmacol 2002; 137: 1314-1320
56. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF et al. PPARalpha and PPARdelta activators inhibit cytokine-Induced nuclear translocation of NFkappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002; 435: 143-151
57. Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen PH, van der Vusse GJ et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-Activated receptors PPARalpha and PPARdelta. J Biol Chem 2008; 283: 29109-29118
58. Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M et al. Activation of peroxisome proliferator-Activated receptor beta/delta inhibits lipopolysaccharide-Induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 2008; 57: 2149-2157